Variable benefit in neuropsychological function in HIV-infected HAART-treated patients

Neurology. 2006 May 9;66(9):1447-50. doi: 10.1212/01.wnl.0000210477.63851.d3.

Abstract

The authors examined cognitive performance change in 101 individuals with advanced HIV infection on highly active antiretroviral therapy (HAART), using standard neuropsychological testing in three visits, over a 27-month-period. Cognitive performance stabilized in a majority of HIV+ participants over time. A neuroactive HAART regimen was associated with neuropsychological improvement. Decline occurred in a minority with lower nadir CD4. The current CD4 count and plasma viral load were not associated with cognitive change.

Publication types

  • Evaluation Study

MeSH terms

  • AIDS Dementia Complex / diagnosis
  • AIDS Dementia Complex / drug therapy*
  • AIDS Dementia Complex / prevention & control
  • AIDS Dementia Complex / psychology
  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / pharmacology
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active*
  • Attention / drug effects
  • CD4 Lymphocyte Count
  • Disease Progression
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy
  • HIV Infections / psychology
  • Humans
  • Male
  • Memory / drug effects
  • Middle Aged
  • Neuropsychological Tests
  • Prevalence
  • Prospective Studies
  • Psychomotor Performance / drug effects
  • Sampling Studies
  • Verbal Learning / drug effects
  • Viral Load

Substances

  • Anti-HIV Agents